AG真人官方

STOCK TITAN
  1. Home
  2. Sec-filings
  3. OBIO
  4. [Form 4] Orchestra BioMed Holdings, Inc. Insider Trading Activity

[Form 4] Orchestra BioMed Holdings, Inc. Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4
Rhea-AI Filing Summary

Orchestra BioMed Holdings (OBIO) director Chris Cleary received new equity compensation grants on June 24, 2025. The awards consist of:

  • 12,422 Restricted Stock Units (RSUs) with a $0 exercise price, bringing total direct ownership to 22,577 shares
  • 36,797 Stock Options with an exercise price of $3.22 per share, expiring June 24, 2035

Both the RSUs and stock options will vest in a single installment at the earlier of: (1) one-year anniversary of grant date or (2) the 2026 Annual Meeting of Stockholders, subject to continued service. This Form 4 filing was submitted by Andrew Taylor as attorney-in-fact on June 26, 2025, reflecting standard director compensation arrangements.

Chris Cleary, direttore di Orchestra BioMed Holdings (OBIO), ha ricevuto nuove concessioni di compensi azionari il 24 giugno 2025. Gli incentivi comprendono:

  • 12.422 Unit脿 di Azioni Vincolate (RSU) con prezzo di esercizio pari a 0$, portando la propriet脿 diretta totale a 22.577 azioni
  • 36.797 Opzioni Azionarie con prezzo di esercizio di 3,22$ per azione, con scadenza il 24 giugno 2035

Sia le RSU che le opzioni azionarie matureranno in un'unica soluzione alla prima delle seguenti date: (1) anniversario di un anno dalla data di concessione oppure (2) Assemblea Annuale degli Azionisti del 2026, subordinatamente alla continuazione del servizio. Questa comunicazione Form 4 猫 stata presentata da Andrew Taylor come procuratore il 26 giugno 2025, riflettendo le consuete modalit脿 di compenso per i direttori.

Chris Cleary, director de Orchestra BioMed Holdings (OBIO), recibi贸 nuevas concesiones de compensaci贸n en acciones el 24 de junio de 2025. Las adjudicaciones consisten en:

  • 12,422 Unidades de Acciones Restringidas (RSU) con precio de ejercicio de $0, aumentando la propiedad directa total a 22,577 acciones
  • 36,797 Opciones sobre Acciones con un precio de ejercicio de $3.22 por acci贸n, que expiran el 24 de junio de 2035

Tanto las RSU como las opciones sobre acciones se consolidar谩n en un solo pago en la fecha que ocurra primero entre: (1) el aniversario de un a帽o desde la fecha de concesi贸n o (2) la Reuni贸n Anual de Accionistas de 2026, sujeto a la continuaci贸n del servicio. Esta presentaci贸n del Formulario 4 fue realizada por Andrew Taylor como apoderado el 26 de junio de 2025, reflejando los arreglos est谩ndar de compensaci贸n para directores.

Orchestra BioMed Holdings(OBIO)鞚� 鞚挫偓 韥Μ鞀� 韥措Μ鞏措Μ臧� 2025雲� 6鞗� 24鞚检棎 靸堧鞖� 欤检嫕 氤挫儊 甓岉暅鞚� 氚涭晿鞀惦媹雼�. 靾橃棳 雮挫棴鞚� 雼れ潓瓿� 臧欖姷雼堧嫟:

  • 12,422 鞝滍暅 欤检嫕 雼渼(RSUs) 頄夓偓臧�瓴� $0, 齑� 歆侅爲 氤挫湢 欤检嫕 靾橂姅 22,577欤茧 歃濌皜
  • 36,797 欤检嫕 鞓奠厴 欤茧嫻 頄夓偓臧�瓴� $3.22, 毵岆鞚检潃 2035雲� 6鞗� 24鞚�

RSU鞕� 欤检嫕 鞓奠厴鞚� 瓿勳啀 攴茧 臁瓣贝頃橃棎 (1) 靾橃棳鞚茧攵�韯� 1雲� 旮半厫鞚� 霕愲姅 (2) 2026雲� 欤检＜齑濏殞 欷� 牍犽ジ 鞁滌爯鞐� 頃� 氩堨棎 氇憪 旆摑霅╇媹雼�. 鞚� Form 4 鞝滌稖鞚� 2025雲� 6鞗� 26鞚� 氩曥爼雽�毽澑鞚� 鞎る摐毳� 韰岇澕霟皜 鞝滌稖頄堨溂氅�, 響滌 鞚挫偓 氤挫儊 臁瓣贝鞚� 氚橃榿頃╇媹雼�.

Chris Cleary, administrateur d'Orchestra BioMed Holdings (OBIO), a re莽u de nouvelles attributions de r茅mun茅ration en actions le 24 juin 2025. Les attributions se composent de :

  • 12 422 unit茅s d'actions restreintes (RSU) avec un prix d'exercice de 0 $, portant la propri茅t茅 directe totale 脿 22 577 actions
  • 36 797 options d'achat d'actions avec un prix d'exercice de 3,22 $ par action, expirant le 24 juin 2035

Les RSU et les options d'achat d'actions seront acquises en une seule fois 脿 la date la plus proche entre : (1) le premier anniversaire de la date d'attribution ou (2) l'assembl茅e g茅n茅rale annuelle des actionnaires de 2026, sous r茅serve de la poursuite du service. Ce d茅p么t du formulaire 4 a 茅t茅 soumis par Andrew Taylor en tant que mandataire le 26 juin 2025, refl茅tant les modalit茅s habituelles de r茅mun茅ration des administrateurs.

Chris Cleary, Direktor von Orchestra BioMed Holdings (OBIO), erhielt am 24. Juni 2025 neue Aktienverg眉tungen. Die Zuteilungen bestehen aus:

  • 12.422 Restricted Stock Units (RSUs) mit einem Aus眉bungspreis von 0 $, wodurch der Gesamtbesitz auf 22.577 Aktien steigt
  • 36.797 Aktienoptionen mit einem Aus眉bungspreis von 3,22 $ pro Aktie, g眉ltig bis zum 24. Juni 2035

Sowohl die RSUs als auch die Aktienoptionen werden in einer einzigen Tranche zum fr眉heren Zeitpunkt von (1) dem einj盲hrigen Jubil盲um des Zuteilungsdatums oder (2) der Hauptversammlung 2026 f盲llig, vorbehaltlich fortgesetzter Dienstzeit. Diese Form 4 Einreichung wurde am 26. Juni 2025 von Andrew Taylor als Bevollm盲chtigter eingereicht und spiegelt die 眉blichen Verg眉tungsregelungen f眉r Direktoren wider.

Positive
  • None.
Negative
  • None.

Chris Cleary, direttore di Orchestra BioMed Holdings (OBIO), ha ricevuto nuove concessioni di compensi azionari il 24 giugno 2025. Gli incentivi comprendono:

  • 12.422 Unit脿 di Azioni Vincolate (RSU) con prezzo di esercizio pari a 0$, portando la propriet脿 diretta totale a 22.577 azioni
  • 36.797 Opzioni Azionarie con prezzo di esercizio di 3,22$ per azione, con scadenza il 24 giugno 2035

Sia le RSU che le opzioni azionarie matureranno in un'unica soluzione alla prima delle seguenti date: (1) anniversario di un anno dalla data di concessione oppure (2) Assemblea Annuale degli Azionisti del 2026, subordinatamente alla continuazione del servizio. Questa comunicazione Form 4 猫 stata presentata da Andrew Taylor come procuratore il 26 giugno 2025, riflettendo le consuete modalit脿 di compenso per i direttori.

Chris Cleary, director de Orchestra BioMed Holdings (OBIO), recibi贸 nuevas concesiones de compensaci贸n en acciones el 24 de junio de 2025. Las adjudicaciones consisten en:

  • 12,422 Unidades de Acciones Restringidas (RSU) con precio de ejercicio de $0, aumentando la propiedad directa total a 22,577 acciones
  • 36,797 Opciones sobre Acciones con un precio de ejercicio de $3.22 por acci贸n, que expiran el 24 de junio de 2035

Tanto las RSU como las opciones sobre acciones se consolidar谩n en un solo pago en la fecha que ocurra primero entre: (1) el aniversario de un a帽o desde la fecha de concesi贸n o (2) la Reuni贸n Anual de Accionistas de 2026, sujeto a la continuaci贸n del servicio. Esta presentaci贸n del Formulario 4 fue realizada por Andrew Taylor como apoderado el 26 de junio de 2025, reflejando los arreglos est谩ndar de compensaci贸n para directores.

Orchestra BioMed Holdings(OBIO)鞚� 鞚挫偓 韥Μ鞀� 韥措Μ鞏措Μ臧� 2025雲� 6鞗� 24鞚检棎 靸堧鞖� 欤检嫕 氤挫儊 甓岉暅鞚� 氚涭晿鞀惦媹雼�. 靾橃棳 雮挫棴鞚� 雼れ潓瓿� 臧欖姷雼堧嫟:

  • 12,422 鞝滍暅 欤检嫕 雼渼(RSUs) 頄夓偓臧�瓴� $0, 齑� 歆侅爲 氤挫湢 欤检嫕 靾橂姅 22,577欤茧 歃濌皜
  • 36,797 欤检嫕 鞓奠厴 欤茧嫻 頄夓偓臧�瓴� $3.22, 毵岆鞚检潃 2035雲� 6鞗� 24鞚�

RSU鞕� 欤检嫕 鞓奠厴鞚� 瓿勳啀 攴茧 臁瓣贝頃橃棎 (1) 靾橃棳鞚茧攵�韯� 1雲� 旮半厫鞚� 霕愲姅 (2) 2026雲� 欤检＜齑濏殞 欷� 牍犽ジ 鞁滌爯鞐� 頃� 氩堨棎 氇憪 旆摑霅╇媹雼�. 鞚� Form 4 鞝滌稖鞚� 2025雲� 6鞗� 26鞚� 氩曥爼雽�毽澑鞚� 鞎る摐毳� 韰岇澕霟皜 鞝滌稖頄堨溂氅�, 響滌 鞚挫偓 氤挫儊 臁瓣贝鞚� 氚橃榿頃╇媹雼�.

Chris Cleary, administrateur d'Orchestra BioMed Holdings (OBIO), a re莽u de nouvelles attributions de r茅mun茅ration en actions le 24 juin 2025. Les attributions se composent de :

  • 12 422 unit茅s d'actions restreintes (RSU) avec un prix d'exercice de 0 $, portant la propri茅t茅 directe totale 脿 22 577 actions
  • 36 797 options d'achat d'actions avec un prix d'exercice de 3,22 $ par action, expirant le 24 juin 2035

Les RSU et les options d'achat d'actions seront acquises en une seule fois 脿 la date la plus proche entre : (1) le premier anniversaire de la date d'attribution ou (2) l'assembl茅e g茅n茅rale annuelle des actionnaires de 2026, sous r茅serve de la poursuite du service. Ce d茅p么t du formulaire 4 a 茅t茅 soumis par Andrew Taylor en tant que mandataire le 26 juin 2025, refl茅tant les modalit茅s habituelles de r茅mun茅ration des administrateurs.

Chris Cleary, Direktor von Orchestra BioMed Holdings (OBIO), erhielt am 24. Juni 2025 neue Aktienverg眉tungen. Die Zuteilungen bestehen aus:

  • 12.422 Restricted Stock Units (RSUs) mit einem Aus眉bungspreis von 0 $, wodurch der Gesamtbesitz auf 22.577 Aktien steigt
  • 36.797 Aktienoptionen mit einem Aus眉bungspreis von 3,22 $ pro Aktie, g眉ltig bis zum 24. Juni 2035

Sowohl die RSUs als auch die Aktienoptionen werden in einer einzigen Tranche zum fr眉heren Zeitpunkt von (1) dem einj盲hrigen Jubil盲um des Zuteilungsdatums oder (2) der Hauptversammlung 2026 f盲llig, vorbehaltlich fortgesetzter Dienstzeit. Diese Form 4 Einreichung wurde am 26. Juni 2025 von Andrew Taylor als Bevollm盲chtigter eingereicht und spiegelt die 眉blichen Verg眉tungsregelungen f眉r Direktoren wider.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Cleary Chris
(Last) (First) (Middle)
C/O ORCHESTRA BIOMED HOLDINGS, INC.
150 UNION SQUARE DRIVE
(Street)
NEW HOPE PA 18938
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Orchestra BioMed Holdings, Inc. [ OBIO ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
06/24/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock, par value $0.0001 per share ("Common Stock") 06/24/2025 A 12,422(1) A $0 22,577 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (Right to Buy) $3.22 06/24/2025 A 36,797 (2) 06/24/2035 Common Stock 36,797 $0 36,797 D
Explanation of Responses:
1. Represents an award of restricted stock units ("RSUs") awarded to the Reporting Person on June 24, 2025 (the "Grant Date"). Each RSU represents a contingent right to receive one share of Common Stock. The RSUs will vest in one installment on the earlier of (x) the one year anniversary of the Grant Date or (y) the date of the Issuer's 2026 Annual Meeting of Stockholders, subject to the Reporting Person's continuous service through such dates.
2. The stock options will vest in one installment on the earlier of (x) the one year anniversary of the Grant Date or (y) the date of the Issuer's 2026 Annual Meeting of Stockholders, subject to the Reporting Person's continuous service through such dates.
/s/ Andrew Taylor, Attorney-in-Fact 06/26/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source:

FAQ

What stock options did OBIO director Chris Cleary receive on June 24, 2025?

Chris Cleary received 36,797 stock options with an exercise price of $3.22 per share. These options will vest in one installment on either the one-year anniversary of the grant date (June 24, 2026) or the date of OBIO's 2026 Annual Meeting of Stockholders, whichever comes first.

How many restricted stock units (RSUs) were granted to Chris Cleary at OBIO?

Chris Cleary was granted 12,422 restricted stock units (RSUs) on June 24, 2025. Each RSU represents one share of common stock and will vest in one installment on either June 24, 2026 or the date of OBIO's 2026 Annual Meeting of Stockholders, whichever occurs first.

When do Chris Cleary's OBIO stock options expire?

The stock options granted to Chris Cleary expire on June 24, 2035, which is 10 years from the grant date of June 24, 2025.

How many shares of OBIO common stock does Chris Cleary own directly after the June 24, 2025 transactions?

Following the reported transactions, Chris Cleary directly owns 22,577 shares of OBIO common stock, plus 12,422 unvested RSUs and 36,797 unvested stock options.
Stock OBIO logo
Orchestra BioMed Holdings Inc

NASDAQ:OBIO

OBIO Rankings

#4473 Ranked by Market Cap
N/A Ranked by Dividends

OBIO Latest News

Aug 26, 2025
Orchestra BioMed Announces Publication of Clinical Data Demonstrating Favorable Blood Pressure and Hemodynamic Effects of AVIM Therapy in JACC: Clinical Electrophysiology
Aug 14, 2025
Orchestra BioMed Announces Publication of AVIM Therapy Clinical Data in JACC: Advances Demonstrating Potential to Improve Cardiac Function in Patients with Hypertension and Diastolic Dysfunction
Aug 12, 2025
Orchestra BioMed Reports Second Quarter 2025 Financial Results and Highlights Recent Business Updates
Aug 8, 2025
Orchestra BioMed Announces Rollout of FDA-Approved BACKBEAT Global Pivotal Study Protocol Update Significantly Expanding Patient Eligibility
Aug 5, 2025
Orchestra BioMed Secures Over $111 Million in Proceeds and Committed Capital Following Completion of Strategic Transactions and Concurrent Public and Private Equity Offerings

OBIO Latest SEC Filings

Aug 25, 2025
[Form 4] Orchestra BioMed Holdings, Inc. Insider Trading Activity
Aug 25, 2025
[Form 4] Orchestra BioMed Holdings, Inc. Insider Trading Activity
Aug 25, 2025
[Form 4] Orchestra BioMed Holdings, Inc. Insider Trading Activity
Aug 25, 2025
[Form 4] Orchestra BioMed Holdings, Inc. Insider Trading Activity
Aug 12, 2025
[10-Q] Orchestra BioMed Holdings, Inc. Quarterly Earnings Report

OBIO Stock Data

140.28M
39.91M
16.19%
34.98%
1.31%
Biotechnology
Surgical & Medical Instruments & Apparatus
United States
NEW HOPE